Nektar Therapeutics Increase (Decrease) in Interest Payable, Net
Nektar Therapeutics (NKTR) reported Increase (Decrease) in Interest Payable, Net of -$54.00 thousand for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInterestPayableNet · last filed 2018-08-09
- Nektar Therapeutics increase (decrease) in interest payable, net for the quarter ending 2018-06-30 was $54.00K, a 0.00% change year-over-year.
- Nektar Therapeutics increase (decrease) in interest payable, net for the quarter ending 2018-03-31 was -$108.00K.
- Nektar Therapeutics increase (decrease) in interest payable, net for the quarter ending 2017-06-30 was $54.00K.
- Nektar Therapeutics increase (decrease) in interest payable, net for the quarter ending 2017-03-31 was -$108.00K.
- Nektar Therapeutics increase (decrease) in interest payable, net for fiscal 2017 was $0.00.
- Nektar Therapeutics increase (decrease) in interest payable, net for fiscal 2016 was $0.00.
- Nektar Therapeutics increase (decrease) in interest payable, net for fiscal 2015 was -$2.72M.
- Nektar Therapeutics increase (decrease) in interest payable, net for fiscal 2014 was $0.00.
| Period end | Increase (Decrease) in Interest Payable, Net 3 month | Increase (Decrease) in Interest Payable, Net 6 month | Increase (Decrease) in Interest Payable, Net 9 month | Increase (Decrease) in Interest Payable, Net 12 month |
|---|---|---|---|---|
| 2018-06-30 | $54.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$54.00K 10-Q · filed 2018-08-09 | ||
| 2018-03-31 | -$108.00K 10-Q · filed 2018-05-10 | |||
| 2017-12-31 | $0.00 10-K · filed 2018-03-01 | |||
| 2017-06-30 | $54.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$54.00K 10-Q · filed 2018-08-09 | -$54.00K derived: sum of 3 quarters · filed 2018-08-09 | $0.00 derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | -$108.00K 10-Q · filed 2018-05-10 | -$108.00K derived: sum of 2 quarters · filed 2018-05-10 | -$54.00K derived: sum of 3 quarters · filed 2018-05-10 | -$54.00K derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $54.00K derived: sum of 2 quarters · filed 2018-03-01 | $54.00K derived: sum of 3 quarters · filed 2018-03-01 | $0.00 10-K · filed 2018-03-01 |
| 2016-09-30 | $54.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $54.00K derived: sum of 2 quarters · filed 2017-08-09 | $0.00 10-Q · filed 2016-11-04 | $1.03M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$54.00K 10-Q · filed 2017-08-09 | $977.00K derived: sum of 3 quarters · filed 2018-03-01 | -$2.77M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | -$54.00K 10-Q · filed 2017-05-10 | $977.00K derived: sum of 2 quarters · filed 2018-03-01 | -$2.77M derived: sum of 3 quarters · filed 2018-03-01 | $977.00K derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$2.72M derived: sum of 2 quarters · filed 2018-03-01 | $1.03M derived: sum of 3 quarters · filed 2018-03-01 | -$2.72M 10-K · filed 2018-03-01 |
| 2015-09-30 | -$3.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $0.00 derived: sum of 2 quarters · filed 2016-11-04 | -$3.75M 10-Q · filed 2016-11-04 | $0.00 derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $3.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $0.00 10-Q · filed 2016-08-04 | $3.75M derived: sum of 3 quarters · filed 2017-03-01 | $0.00 derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | -$3.75M 10-Q · filed 2016-05-04 | $0.00 derived: sum of 2 quarters · filed 2017-03-01 | -$3.75M derived: sum of 3 quarters · filed 2017-03-01 | $0.00 derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $0.00 derived: sum of 2 quarters · filed 2017-03-01 | $3.75M derived: sum of 3 quarters · filed 2017-03-01 | $0.00 10-K · filed 2017-03-01 |
| 2014-09-30 | -$3.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $0.00 derived: sum of 2 quarters · filed 2015-11-06 | -$3.75M 10-Q · filed 2015-11-06 | $0.00 derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $3.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-01 | $0.00 10-Q · filed 2014-08-01 | $3.75M derived: sum of 3 quarters · filed 2016-02-29 | $0.00 derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | -$3.75M 10-Q · filed 2015-05-01 | $0.00 derived: sum of 2 quarters · filed 2016-02-29 | -$3.75M derived: sum of 3 quarters · filed 2016-02-29 | $0.00 derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $0.00 derived: sum of 2 quarters · filed 2016-02-29 | $3.75M derived: sum of 3 quarters · filed 2016-02-29 | -$166.00K 10-K · filed 2016-02-29 |
| 2013-09-30 | -$3.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $0.00 derived: sum of 2 quarters · filed 2014-11-07 | -$3.92M 10-Q · filed 2014-11-07 | -$166.00K derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-06-30 | $3.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-01 | -$166.00K 10-Q · filed 2014-08-01 | $3.58M derived: sum of 3 quarters · filed 2015-02-26 | |
| 2013-03-31 | -$3.92M 10-Q · filed 2014-05-08 | -$166.00K derived: sum of 2 quarters · filed 2015-02-26 | ||
| 2012-12-31 | $3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $5.28M 10-K · filed 2015-02-26 | ||
| 2012-09-30 | $1.53M 10-Q · filed 2013-11-07 | |||
| 2012-03-31 | -$1.75M 10-Q · filed 2013-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |